CRLBFCresco Labs Inc.
The schedule
- Thu15Oct
The market will closely digest any regulatory rhetoric from the Trump administration regarding 280E tax reform or federal rescheduling. Favorable progress could spark a relief rally to $0.85, whereas a hardline stance or continued stagnation risks pushing the stock down to $0.50.
- Tue3Nov
Voters across several key states will decide on adult-use legalization, potentially expanding Cresco's total addressable market. Sweeping approvals could expand the retail footprint narrative and lift shares to $0.70, while sweeping defeats would solidify the bear floor at $0.40.
- Sun14Feb
Q3 results will reveal the impact of back-to-school and early holiday demand on wholesale and retail revenue. If same-store sales growth offsets margin compression, shares could test $0.85. Continued cash burn will send the stock toward $0.85.
- Fri7May
Q1 2027 earnings will test management's ability to drive organic growth without compromising margins. Delivery of positive EPS and debt reduction progress targets $0.95, while missing the consensus EPS marks a $0.60 fallback.
- Sat22May
Q4 results will provide a full-year review of FY2026 cost-cutting measures and 2027 margin guidance. A reaffirmed or elevated forward outlook with clear cash generation could lift the stock to $0.75, whereas soft guidance will result in a drop to $0.45.
Past
- Wed30Sep
With $588M in debt, an update on refinancing or restructuring is critical. Management must address upcoming maturities in a 3.63% Fed Funds environment. A favorable term sheet could drive shares to $1.00, while punitive or dilutive financing risks a drop to $0.65.
- Thu13Aug
Actual outcome: Bear · $0.79 at outcome
Cresco Labs reported Q2 2026 results featuring $173 million in revenue and $40 million in Adjusted EBITDA, alongside EPS that met or slightly beat expectations. Despite these stable operational figures, the stock drifted lower and breached the $0.80 bear floor. The earnings report failed to provide the strong margin improvement or free cash flow generation needed to alleviate market concerns over the company's substantial $588 million debt load, resulting in a bearish outcome.
Q2 2026 earnings will focus on cost-cutting execution and free cash flow generation as Cresco attempts to manage its $588M debt load. With Q1 reporting a net loss of $12.8M, the market needs to see margin improvement to maintain a $1.15 target, or it risks falling to $0.80.
- Fri8May
Actual outcome: Bear · $0.95 at outcome
Stock fell 8.7% from event to outcome date, aligning with the bear trajectory.
Q1 2026 earnings and the first detailed 2026 outlook will be a key check on Cresco Labs Inc.'s ability to stabilize revenue and sustain positive free cash flow at around $1.18 per share, with a bullish scenario toward $1.70 if margins and cash generation improve, and downside risk toward $1.70 if revenue continues to contract or guidance is cautious.
